Defeating cancer together: our policy priorities
We believe there are three areas the Government could prioritise to enable cancer research in academic institutions to thrive, and help us on our mission to continue making the discoveries that defeat cancer.
"We need the Government to use all available policy levers to support the sector and help cancer research in UK academic institutions thrive."
- Professor Kristian Helin, Chief Executive, The Institute of Cancer Research
"100 days in - it is vital that this new Parliament comes together to prioritise cancer research. For all of us affected by cancer, research is where hope starts, Parliament can help catalyse this hope"
- Sue Duncombe, Cancer Patient Advocate
Advocacy blog posts
The Charity Research Support Fund: An overlooked, and neglected, lifeline for UK science
Ollie Richards, Advocacy Manager at the ICR, explores how a critical element of the Government's research funding – the Charity Research Support Fund – could be reformed to help support more specialist institutions and universities to do life-saving research.
100 days in – what do we need from the Government to enable cancer research to thrive?
We’re now 100 days into the new Government and the ICR’s Advocacy Manager, Ollie Richards, outlines what academic institutions need the Government to prioritise to help us on our mission to continue making the discoveries that defeat cancer.
Latest ICR News
Remembering Professor Robin Weiss: a pioneer of viral oncology and former ICR Director
Professor Robin Weiss, recognised as one of the most influential scientists in modern virology and cancer biology, passed away on 27 February 2026.
Study reveals how an editing enzyme causes abnormal gene activity in hormone-driven breast cancer
Researchers have uncovered a previously unknown mechanism that allows breast cancer to exploit day-to-day gene activity to fuel its growth. This finding reveals how hormone-driven breast cancers develop and adapt to treatment.
National breast cancer audit helps inform debate over surgical margins for ductal carcinoma in situ
A large national study has provided some of the strongest evidence yet on how much healthy tissue should be removed when treating ductal carcinoma in situ (DCIS) with breast-conserving surgery – helping to resolve a long-running clinical debate and prompting changes to the Association of Breast Surgeons guidance.